Our Solutions

Immunity Scoring

Protective Immunity Intelligence That Matters

Monitoring and reprogramming the immune system

Using innovative technology developed by world leading research institutions, AditxtScore provides personalized quantitative data to determine protective immunity status.

What it is

Aditxt Therapeutics, Inc. (“Aditxt”) is a Medivolve channel partner offering COVID-19 immunity status monitoring through Medivolve’s Test Before You Go Mobile Testing Centers.

Aditxt is a biotech innovation company with a mission to prolong life and enhance its quality by improving immune system health-specifically by developing technologies focused on immune reprogramming and monitoring.

Strategic Growth Imperative

While vaccinations will decrease the likelihood of contracting COVID-19 and any potential of spreading it, the immunization process differs from person to person. The only way to know if you are truly safe from contracting and spreading COVID is to have insight into your unique immune system. Never have we had access to immunity monitoring technology that is efficient, practical and scalable…until now.

At Medivolve, we’re united by a powerful, singular purpose: harnessing the transformative power of technology to create healthier lives. With Aditxt, Medivolve is helping to give people a holistic and empowered view of their personal health and greater control in managing it.

Why it Matters

“As the rollout of COVID-19 vaccines progress across the United States, people are going to want to monitor their immunity levels regularly. This will be one of the many ongoing services offered through our future telehealth sites as immune responsiveness will be top of mind for people for the foreseeable future. We are excited to be able to bring this testing modality to our customers and believe it will be a significant revenue contributor over the coming now and in the future.” – Doug Sommerville, former CEO, Medivolve

Join Medivolve's Investor Mailing List Today

Stay up to date on the latest developments and breakthroughs.

In accordance with Canada’s anti-spam legislation, by sending us your email address and other personal information you consent to receiving communications from us related to our business, operations and certain investment opportunities, but only to the extent that you qualify to participate in any such opportunities. You also consent to us sharing your personal information with third-party marketing companies strictly for the purposes set out above. You may revoke your consent at any time by emailing us at [email protected]. You further confirm that you are not a resident of any country in the European Economic Area.